<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02081014</url>
  </required_header>
  <id_info>
    <org_study_id>XSMP-201</org_study_id>
    <secondary_id>1R44DK096715-01A1</secondary_id>
    <nct_id>NCT02081014</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Mini-Dose Glucagon (G-Pen Mini) in Patients With Type 1 Diabetes</brief_title>
  <official_title>A Randomized, Phase 2a, Blinded, 3-Way Crossover Dose-Ranging Study With G-Pen Mini™ (Glucagon Injection) to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Type 1 Diabetes Mellitus (T1DM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xeris Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Emissary International LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Xeris Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to demonstrate that mini-doses of stable liquid glucagon (G-Pen
      Mini) produced by Xeris Pharmaceuticals are safe and effective as a treatment for mild to
      moderate hypoglycemia, a complication of diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>From first dose until follow-up call, up to 7 weeks per subject</time_frame>
    <description>Number of serious adverse events (SAEs) per treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucagon Cmax (Fasting)</measure>
    <time_frame>Approximately 15 and 0 minutes before each injection and at 5, 10, 15, 20, 30, 45, 60, 120 and 180 minutes post-injection</time_frame>
    <description>Pharmacokinetic parameter: Maximum concentration of glucagon</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucagon Cmax (Post-insulin)</measure>
    <time_frame>Approximately 15 and 0 minutes before each injection and at 5, 10, 15, 20, 30, 45, 60, and 120 minutes post-injection</time_frame>
    <description>Pharmacokinetic parameter: Maximum concentration of glucagon</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucagon Area Under the Curve (AUC) (Fasting)</measure>
    <time_frame>Approximately 15 and 0 minutes before each injection and at 5, 10, 15, 20, 30, 45, 60, and 120 minutes post-injection</time_frame>
    <description>Pharmacokinetic parameter: Area under the glucagon concentration curve from 0 to 120 minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucagon AUC (Post-insulin)</measure>
    <time_frame>Approximately 15 and 0 minutes before each injection and at 5, 10, 15, 20, 30, 45, 60, and 120 minutes post-injection</time_frame>
    <description>Pharmacokinetic parameter: Area under the glucagon concentration curve from 0 to 120 minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucagon Tmax (Fasting)</measure>
    <time_frame>Approximately 15 and 0 minutes before each injection and at 5, 10, 15, 20, 30, 45, 60, 120 and 180 minutes post-injection</time_frame>
    <description>Pharmacokinetic parameter: Time to reach maximum concentration of glucagon</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucagon Tmax (Post-insulin)</measure>
    <time_frame>Approximately 15 and 0 minutes before each injection and at 5, 10, 15, 20, 30, 45, 60, and 120 minutes post-injection</time_frame>
    <description>Pharmacokinetic parameter: Time to reach maximum concentration of glucagon</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose Cmax (Fasting)</measure>
    <time_frame>Approximately 15 and 0 minutes before each injection and at 5, 10, 15, 20, 30, 45, 60, 120 and 180 minutes post-injection</time_frame>
    <description>Pharmacodynamic parameter: Maximum concentration of glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose Cmax (Post-insulin)</measure>
    <time_frame>Approximately 15 and 0 minutes before each injection and at 5, 10, 15, 20, 30, 45, 60, and 120 minutes post-injection</time_frame>
    <description>Pharmacodynamic parameter: Maximum concentration of glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose AUC (Fasting)</measure>
    <time_frame>Approximately 15 and 0 minutes before each injection and at 5, 10, 15, 20, 30, 45, 60, and 120 minutes post-injection</time_frame>
    <description>Pharmacodynamic parameter: baseline adjusted area under the glucagon concentration curve from 0 to 120 minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose AUC (Post-insulin)</measure>
    <time_frame>Approximately 15 and 0 minutes before each injection and at 5, 10, 15, 20, 30, 45, 60, and 120 minutes post-injection</time_frame>
    <description>Pharmacodynamic parameter: baseline adjusted area under the glucose concentration curve from 0-120 minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose Tmax (Fasting)</measure>
    <time_frame>Approximately 15 and 0 minutes before each injection and at 5, 10, 15, 20, 30, 45, 60, 120 and 180 minutes post-injection</time_frame>
    <description>Pharmacodynamic parameter: Time to reach maximum concentration of glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose Tmax (Post-insulin)</measure>
    <time_frame>Approximately 15 and 0 minutes before each injection and at 5, 10, 15, 20, 30, 45, 60, and 120 minutes post-injection</time_frame>
    <description>Pharmacodynamic parameter: Time to reach maximum concentration of glucose</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Hypoglycemia</condition>
  <arm_group>
    <arm_group_label>G-Pen Mini™ (glucagon injection) 75 ug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>G-Pen Mini™ (glucagon injection), two 75 microgram subcutaneous injections given approximately 4-5 hours apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>G-Pen Mini™ (glucagon injection) 150 ug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>G-Pen Mini™ (glucagon injection), two 150 microgram subcutaneous injections given approximately 4-5 hours apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>G-Pen Mini™ (glucagon injection) 300 ug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>G-Pen Mini™ (glucagon injection), two 300 microgram subcutaneous injections given approximately 4-5 hours apart</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-Pen Mini™ (glucagon injection)</intervention_name>
    <description>stable, pre-mixed, liquid glucagon for subcutaneous injection</description>
    <arm_group_label>G-Pen Mini™ (glucagon injection) 75 ug</arm_group_label>
    <arm_group_label>G-Pen Mini™ (glucagon injection) 150 ug</arm_group_label>
    <arm_group_label>G-Pen Mini™ (glucagon injection) 300 ug</arm_group_label>
    <other_name>mini-dose glucagon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female subjects on insulin infusion pump therapy for treatment of type 1
             diabetes

          2. Between the ages of 18 and 50 years of age, inclusive, at Screening.

          3. Females of childbearing potential with a negative serum pregnancy test prior at
             screening and negative urine pregnancy tests prior to the Treatment visits, using an
             approved forms of contraception for the duration of participation in the study (i.e.
             until after last dose).

          4. Male subjects are required to use a condom and another of the methods of contraception
             in #3 above starting at Randomization and for the duration of the study.

          5. Hemoglobin A1c (HbA1c) &lt; 9.0 %.

          6. Evidence of a personally signed and dated informed consent document indicating that
             the subject has been informed of all pertinent aspects of the study.

          7. Subjects must be willing and able to comply with scheduled visits, treatment,
             laboratory tests and study procedures.

        Exclusion Criteria:

          1. Clinical evidence of microvascular complication(s) other than mild microalbuminuria or
             history of mild non-proliferative retinopathy

          2. Any chronic diseases or illness that interferes with glucose metabolism, except for
             T1DM, or medications other than hypothyroidism on appropriate thyroid hormone
             replacement.

          3. Blood pressure (BP) readings at Screening where Systemic BP &lt;90 or &gt;140 mm Hg, and
             Diastolic BP &lt;50 or &gt;90 mm Hg.

          4. Cardiovascular event within 6 months prior to screening such as unstable angina, acute
             coronary syndrome, myocardial infarction, therapeutic coronary procedure (e.g., stent
             placement, Percutaneous Transluminal Coronary Angioplasty (PTCA), Coronary Artery
             By-pass Grafting (CABG)), stroke or transient ischemic attack.

          5. Study participants who are pregnant at Screening.

          6. Breast feeding must be discontinued if a subject wishes to participate in this study.

          7. Positive test for hepatitis B, hepatitis C, or HIV found at Screening.

          8. Positive urine drug test for illicit drugs at Screening.

          9. History of allergies to glucagon, glucagon-like products or to any of the excipients
             in the investigational formulation.

         10. Known presence of hereditary problems of glycogen storage disease, galactose and /or
             lactose intolerance

         11. Administration of glucagon more than once within the three (3) months prior to
             Screening

         12. Subjects with any of the following abnormalities in clinical laboratory tests at
             Screening, confirmed by a single repeat, if necessary:

               -  Hemoglobin (Hb) below the lower limits of normal for the laboratory

               -  Total bilirubin above the upper limits of normal for the laboratory

               -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) above the
                  upper limits of normal for the laboratory

               -  Creatinine above the upper limits of normal for the laboratory

         13. History of regular alcohol consumption as defined by alcohol intake in a quantity
             exceeding 7 drinks per week for females or 14 drinks per week for males, where 1 drink
             = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of
             hard liquor.

         14. Participation in other studies involving administration of an investigational drug or
             device within 30 days or 5 half-lives, whichever is longer, before screening for the
             current study and during participation in the current study

         15. Whole blood donation of 1 pint (500 mL) within 8 weeks prior to Screening. Donations
             of plasma, packed red blood cells, platelets or quantities less than 500 mL are
             allowed at investigator discretion.

         16. Other severe acute or chronic medical or psychiatric condition or laboratory
             abnormality that may increase the risk associated with study participation or
             investigational product administration or may interfere with the interpretation of
             study results and, in the judgment of the investigator, would make the subject
             inappropriate for entry into this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Morey W Haymond, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baylor College of Medicine, Children's Nutritional Research Center, Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Haymond MW, Redondo MJ, McKay S, Cummins MJ, Newswanger B, Kinzell J, Prestrelski S. Nonaqueous, Mini-Dose Glucagon for Treatment of Mild Hypoglycemia in Adults With Type 1 Diabetes: A Dose-Seeking Study. Diabetes Care. 2016 Mar;39(3):465-8. doi: 10.2337/dc15-2124. Epub 2016 Feb 9.</citation>
    <PMID>26861921</PMID>
  </results_reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2014</study_first_submitted>
  <study_first_submitted_qc>March 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2014</study_first_posted>
  <results_first_submitted>April 8, 2016</results_first_submitted>
  <results_first_submitted_qc>April 8, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 16, 2016</results_first_posted>
  <last_update_submitted>March 10, 2018</last_update_submitted>
  <last_update_submitted_qc>March 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypoglycemia</keyword>
  <keyword>Glucagon</keyword>
  <keyword>Diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 13 adults &lt; 50 years of age with type 1 diabetes were recruited over a period of 5 months to receive treatment at a university-affiliated state hospital-based endocrinology clinic.</recruitment_details>
      <pre_assignment_details>A total of 13 subjects were randomized to treatment. Due to poor venous access an IV could not be started in one subject, so only 12 subjects received treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>G-Pen Mini™ Dose Order: 75, 150 &amp; 300 Micrograms</title>
          <description>G-Pen Mini™ (glucagon injection): two 75 microgram (ug) subcutaneous (SC) injections at treatment visit 1, followed by a 2-21 day washout, then two 150 ug SC injections at treatment visit 2, followed by a 2-21 day washout, and finally two 300 ug SC injections at treatment visit 3.</description>
        </group>
        <group group_id="P2">
          <title>G-Pen Mini™ Dose Order: 75, 300 &amp; 150 Micrograms</title>
          <description>G-Pen Mini™ (glucagon injection): two 75 ug SC injections at treatment visit 1, followed by a 2-21 day washout, then two 300 ug SC injections at treatment visit 2, followed by a 2-21 day washout, and finally two 150 ug SC injections at treatment visit 3.</description>
        </group>
        <group group_id="P3">
          <title>G-Pen Mini™ Dose Order: 150, 75 &amp; 300 Micrograms</title>
          <description>G-Pen Mini™ (glucagon injection): two 150 ug SC injections at treatment visit 1, followed by a 2-21 day washout, then two 75 ug SC injections at treatment visit 2, followed by a 2-21 day washout, and finally two 300 ug SC injections at treatment visit 3.</description>
        </group>
        <group group_id="P4">
          <title>G-Pen Mini™ Dose Order: 150, 300 &amp; 75 Micrograms</title>
          <description>G-Pen Mini™ (glucagon injection): two 150 ug SC injections at treatment visit 1, followed by a 2-21 day washout, then two 300 ug SC injections at treatment visit 2, followed by a 2-21 day washout, and finally two 150 ug SC injections at treatment visit 3.</description>
        </group>
        <group group_id="P5">
          <title>G-Pen Mini™ Dose Order: 300, 75 &amp; 150 Micrograms</title>
          <description>G-Pen Mini™ (glucagon injection): two 300 ug SC injections at treatment visit 1, followed by a 2-21 day washout, then two 75 ug SC injections at treatment visit 2, followed by a 2-21 day washout, and finally two 150 ug SC injections at treatment visit 3.</description>
        </group>
        <group group_id="P6">
          <title>G-Pen Mini™ Dose Order: 300, 150 &amp; 75 Micrograms</title>
          <description>G-Pen Mini™ (glucagon injection): two 300 ug SC injections at treatment visit 1, followed by a 2-21 day washout, then two 150 ug SC injections at treatment visit 2, followed by a 2-21 day washout, and finally two 75 ug SC injections at treatment visit 3.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized subjects who received at least one dose of study drug</population>
      <group_list>
        <group group_id="B1">
          <title>Total Study Group</title>
          <description>Includes all 12 treated subjects</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.4" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HbA1c</title>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.7" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.6" spread="12.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Diabetes</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.6" spread="6.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Serious Adverse Events</title>
        <description>Number of serious adverse events (SAEs) per treatment</description>
        <time_frame>From first dose until follow-up call, up to 7 weeks per subject</time_frame>
        <population>All randomized subjects who received at least one dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>G-Pen Mini™ (Glucagon Injection) 75 ug</title>
            <description>G-Pen Mini™ (glucagon injection), two 75 microgram subcutaneous injections given approximately 4-5 hours apart</description>
          </group>
          <group group_id="O2">
            <title>G-Pen Mini™ (Glucagon Injection) 150 ug</title>
            <description>G-Pen Mini™ (glucagon injection), two 150 microgram subcutaneous injections given approximately 4-5 hours apart</description>
          </group>
          <group group_id="O3">
            <title>G-Pen Mini™ (Glucagon Injection) 300 ug</title>
            <description>G-Pen Mini™ (glucagon injection), two 300 microgram subcutaneous injections given approximately 4-5 hours apart</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Adverse Events</title>
          <description>Number of serious adverse events (SAEs) per treatment</description>
          <population>All randomized subjects who received at least one dose of study drug</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucagon Cmax (Fasting)</title>
        <description>Pharmacokinetic parameter: Maximum concentration of glucagon</description>
        <time_frame>Approximately 15 and 0 minutes before each injection and at 5, 10, 15, 20, 30, 45, 60, 120 and 180 minutes post-injection</time_frame>
        <population>All randomized subjects who received at least one dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>G-Pen Mini™ (Glucagon Injection) 75 ug</title>
            <description>G-Pen Mini™ (glucagon injection), a single 75 microgram subcutaneous injection given to subjects after an overnight fast</description>
          </group>
          <group group_id="O2">
            <title>G-Pen Mini™ (Glucagon Injection) 150 ug</title>
            <description>G-Pen Mini™ (glucagon injection), a single 150 microgram subcutaneous injection given given to subjects after an overnight fast</description>
          </group>
          <group group_id="O3">
            <title>G-Pen Mini™ (Glucagon Injection) 300 ug</title>
            <description>G-Pen Mini™ (glucagon injection), a single 300 microgram subcutaneous injection given given to subjects after an overnight fast</description>
          </group>
        </group_list>
        <measure>
          <title>Glucagon Cmax (Fasting)</title>
          <description>Pharmacokinetic parameter: Maximum concentration of glucagon</description>
          <population>All randomized subjects who received at least one dose of study drug</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="233.8" spread="34"/>
                    <measurement group_id="O2" value="380.7" spread="34"/>
                    <measurement group_id="O3" value="663.6" spread="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Point estimate ratio</param_type>
            <param_value>0.62</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.07</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Geometric means</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Point estimate ratio</param_type>
            <param_value>0.35</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.04</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Geometric means</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Point estimate ratio</param_type>
            <param_value>0.57</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.06</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Geometric means</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucagon Cmax (Post-insulin)</title>
        <description>Pharmacokinetic parameter: Maximum concentration of glucagon</description>
        <time_frame>Approximately 15 and 0 minutes before each injection and at 5, 10, 15, 20, 30, 45, 60, and 120 minutes post-injection</time_frame>
        <population>All randomized subject who received at least one dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>G-Pen Mini™ (Glucagon Injection) 75 ug</title>
            <description>G-Pen Mini™ (glucagon injection), a single 75 microgram subcutaneous injection given to subjects in a state of mild hypoglycemia</description>
          </group>
          <group group_id="O2">
            <title>G-Pen Mini™ (Glucagon Injection) 150 ug</title>
            <description>G-Pen Mini™ (glucagon injection), a single 150 microgram subcutaneous injection given to subjects in a state of mild hypoglycemia</description>
          </group>
          <group group_id="O3">
            <title>G-Pen Mini™ (Glucagon Injection) 300 ug</title>
            <description>G-Pen Mini™ (glucagon injection), a single 300 microgram subcutaneous injection given to subjects in a state of mild hypoglycemia</description>
          </group>
        </group_list>
        <measure>
          <title>Glucagon Cmax (Post-insulin)</title>
          <description>Pharmacokinetic parameter: Maximum concentration of glucagon</description>
          <population>All randomized subject who received at least one dose of study drug</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="253.4" spread="30.1"/>
                    <measurement group_id="O2" value="335.4" spread="30.1"/>
                    <measurement group_id="O3" value="561.7" spread="29.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Point estimate ratio</param_type>
            <param_value>0.74</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.06</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Geometric means</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Point estimate ratio</param_type>
            <param_value>0.44</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.04</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Geometric means</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Point estimate ratio</param_type>
            <param_value>0.59</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.05</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Geometric means</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucagon Area Under the Curve (AUC) (Fasting)</title>
        <description>Pharmacokinetic parameter: Area under the glucagon concentration curve from 0 to 120 minutes</description>
        <time_frame>Approximately 15 and 0 minutes before each injection and at 5, 10, 15, 20, 30, 45, 60, and 120 minutes post-injection</time_frame>
        <population>All randomized subjects who received at least one dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>G-Pen Mini™ (Glucagon Injection) 75 ug</title>
            <description>G-Pen Mini™ (glucagon injection), a single 75 microgram subcutaneous injection given to subjects after an overnight fast</description>
          </group>
          <group group_id="O2">
            <title>G-Pen Mini™ (Glucagon Injection) 150 ug</title>
            <description>G-Pen Mini™ (glucagon injection), a single 150 microgram subcutaneous injection given given to subjects after an overnight fast</description>
          </group>
          <group group_id="O3">
            <title>G-Pen Mini™ (Glucagon Injection) 300 ug</title>
            <description>G-Pen Mini™ (glucagon injection), a single 300 microgram subcutaneous injection given given to subjects after an overnight fast</description>
          </group>
        </group_list>
        <measure>
          <title>Glucagon Area Under the Curve (AUC) (Fasting)</title>
          <description>Pharmacokinetic parameter: Area under the glucagon concentration curve from 0 to 120 minutes</description>
          <population>All randomized subjects who received at least one dose of study drug</population>
          <units>(pg/ml)*hour</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="265.4" spread="35.4"/>
                    <measurement group_id="O2" value="389.6" spread="35.4"/>
                    <measurement group_id="O3" value="735.3" spread="35.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Point point ratio</param_type>
            <param_value>0.68</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.05</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Geometric means</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Point estimate ratio</param_type>
            <param_value>0.36</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.03</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Geometric means</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Point estimate ratio</param_type>
            <param_value>0.53</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.04</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Geometric means</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucagon AUC (Post-insulin)</title>
        <description>Pharmacokinetic parameter: Area under the glucagon concentration curve from 0 to 120 minutes</description>
        <time_frame>Approximately 15 and 0 minutes before each injection and at 5, 10, 15, 20, 30, 45, 60, and 120 minutes post-injection</time_frame>
        <population>All randomized subjects who received at least one dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>G-Pen Mini™ (Glucagon Injection) 75 ug</title>
            <description>G-Pen Mini™ (glucagon injection), a single 75 microgram subcutaneous injection given to subjects in a state of mild hypoglycemia</description>
          </group>
          <group group_id="O2">
            <title>G-Pen Mini™ (Glucagon Injection) 150 ug</title>
            <description>G-Pen Mini™ (glucagon injection), a single 150 microgram subcutaneous injection given to subjects in a state of mild hypoglycemia</description>
          </group>
          <group group_id="O3">
            <title>G-Pen Mini™ (Glucagon Injection) 300 ug</title>
            <description>G-Pen Mini™ (glucagon injection), a single 300 microgram subcutaneous injection given to subjects in a state of mild hypoglycemia</description>
          </group>
        </group_list>
        <measure>
          <title>Glucagon AUC (Post-insulin)</title>
          <description>Pharmacokinetic parameter: Area under the glucagon concentration curve from 0 to 120 minutes</description>
          <population>All randomized subjects who received at least one dose of study drug</population>
          <units>(pg/ml)*hour</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="277.4" spread="29.9"/>
                    <measurement group_id="O2" value="386.8" spread="29.9"/>
                    <measurement group_id="O3" value="635.3" spread="29.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Point estimate ratio</param_type>
            <param_value>0.72</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.04</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Geometric means</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Point estimate ratio</param_type>
            <param_value>0.44</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.02</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Geometric means</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Point estimate ratio</param_type>
            <param_value>0.60</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.03</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Geometric means</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucagon Tmax (Fasting)</title>
        <description>Pharmacokinetic parameter: Time to reach maximum concentration of glucagon</description>
        <time_frame>Approximately 15 and 0 minutes before each injection and at 5, 10, 15, 20, 30, 45, 60, 120 and 180 minutes post-injection</time_frame>
        <population>All randomized subjects who received at least one dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>G-Pen Mini™ (Glucagon Injection) 75 ug</title>
            <description>G-Pen Mini™ (glucagon injection), a single 75 microgram subcutaneous injection given fo subjects following an overnight fast</description>
          </group>
          <group group_id="O2">
            <title>G-Pen Mini™ (Glucagon Injection) 150 ug</title>
            <description>G-Pen Mini™ (glucagon injection), a single 150 microgram subcutaneous injection given fo subjects following an overnight fast</description>
          </group>
          <group group_id="O3">
            <title>G-Pen Mini™ (Glucagon Injection) 300 ug</title>
            <description>G-Pen Mini™ (glucagon injection), a single 300 microgram subcutaneous injection given fo subjects following an overnight fast</description>
          </group>
        </group_list>
        <measure>
          <title>Glucagon Tmax (Fasting)</title>
          <description>Pharmacokinetic parameter: Time to reach maximum concentration of glucagon</description>
          <population>All randomized subjects who received at least one dose of study drug</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.2" spread="3.6"/>
                    <measurement group_id="O2" value="29.8" spread="3.6"/>
                    <measurement group_id="O3" value="36.5" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Point esimate ratio</param_type>
            <param_value>0.98</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.14</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Geometric means</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Point estimate ratio</param_type>
            <param_value>0.78</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.11</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Geometric means</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Point estimate ratio</param_type>
            <param_value>0.79</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.11</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Geometric means</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucagon Tmax (Post-insulin)</title>
        <description>Pharmacokinetic parameter: Time to reach maximum concentration of glucagon</description>
        <time_frame>Approximately 15 and 0 minutes before each injection and at 5, 10, 15, 20, 30, 45, 60, and 120 minutes post-injection</time_frame>
        <population>All randomized subjects who received at least one dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>G-Pen Mini™ (Glucagon Injection) 75 ug</title>
            <description>G-Pen Mini™ (glucagon injection), a single 75 microgram subcutaneous injection given to subjects in a state of mild hypoglycemia</description>
          </group>
          <group group_id="O2">
            <title>G-Pen Mini™ (Glucagon Injection) 150 ug</title>
            <description>G-Pen Mini™ (glucagon injection), a single 150 microgram subcutaneous injection given to subjects in a state of mild hypoglycemia</description>
          </group>
          <group group_id="O3">
            <title>G-Pen Mini™ (Glucagon Injection) 300 ug</title>
            <description>G-Pen Mini™ (glucagon injection), a single 300 microgram subcutaneous injection given to subjects in a state of mild hypoglycemia</description>
          </group>
        </group_list>
        <measure>
          <title>Glucagon Tmax (Post-insulin)</title>
          <description>Pharmacokinetic parameter: Time to reach maximum concentration of glucagon</description>
          <population>All randomized subjects who received at least one dose of study drug</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" spread="2.7"/>
                    <measurement group_id="O2" value="33.1" spread="2.7"/>
                    <measurement group_id="O3" value="34.1" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Point estimate ratio</param_type>
            <param_value>0.75</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.10</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Geometric means</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Point estimate ratio</param_type>
            <param_value>0.73</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.10</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Geometric means</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Point estimate ratio</param_type>
            <param_value>0.96</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Geometric means</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucose Cmax (Fasting)</title>
        <description>Pharmacodynamic parameter: Maximum concentration of glucose</description>
        <time_frame>Approximately 15 and 0 minutes before each injection and at 5, 10, 15, 20, 30, 45, 60, 120 and 180 minutes post-injection</time_frame>
        <population>All randomized subjects who received at least one dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>G-Pen Mini™ (Glucagon Injection) 75 ug</title>
            <description>G-Pen Mini™ (glucagon injection), a single 75 microgram subcutaneous injection given to subjects after an overnight fast</description>
          </group>
          <group group_id="O2">
            <title>G-Pen Mini™ (Glucagon Injection) 150 ug</title>
            <description>G-Pen Mini™ (glucagon injection), a single 150 microgram subcutaneous injection given given to subjects after an overnight fast</description>
          </group>
          <group group_id="O3">
            <title>G-Pen Mini™ (Glucagon Injection) 300 ug</title>
            <description>G-Pen Mini™ (glucagon injection), a single 300 microgram subcutaneous injection given given to subjects after an overnight fast</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose Cmax (Fasting)</title>
          <description>Pharmacodynamic parameter: Maximum concentration of glucose</description>
          <population>All randomized subjects who received at least one dose of study drug</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155.1" spread="11.2"/>
                    <measurement group_id="O2" value="186.2" spread="11.1"/>
                    <measurement group_id="O3" value="213.5" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Point estimate ratio</param_type>
            <param_value>0.82</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.06</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Geometric means</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Point estimate ratio</param_type>
            <param_value>0.70</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.05</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Geometric means</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Point estimate ratio</param_type>
            <param_value>0.85</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.06</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Geometric means</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucose Cmax (Post-insulin)</title>
        <description>Pharmacodynamic parameter: Maximum concentration of glucose</description>
        <time_frame>Approximately 15 and 0 minutes before each injection and at 5, 10, 15, 20, 30, 45, 60, and 120 minutes post-injection</time_frame>
        <population>All randomized subjects who received at least one dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>G-Pen Mini™ (Glucagon Injection) 75 ug</title>
            <description>G-Pen Mini™ (glucagon injection), a single 75 microgram subcutaneous injection given to subjects in a state of mild hypoglycemia</description>
          </group>
          <group group_id="O2">
            <title>G-Pen Mini™ (Glucagon Injection) 150 ug</title>
            <description>G-Pen Mini™ (glucagon injection), a single 150 microgram subcutaneous injection given to subjects in a state of mild hypoglycemia</description>
          </group>
          <group group_id="O3">
            <title>G-Pen Mini™ (Glucagon Injection) 300 ug</title>
            <description>G-Pen Mini™ (glucagon injection), a single 300 microgram subcutaneous injection given to subjects in a state of mild hypoglycemia</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose Cmax (Post-insulin)</title>
          <description>Pharmacodynamic parameter: Maximum concentration of glucose</description>
          <population>All randomized subjects who received at least one dose of study drug</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.7" spread="8.6"/>
                    <measurement group_id="O2" value="105.7" spread="8.6"/>
                    <measurement group_id="O3" value="122.6" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Point estimate ratio</param_type>
            <param_value>0.96</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.08</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Geometric means</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Point estimate ratio</param_type>
            <param_value>0.83</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.06</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Geometric means</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Point estimate ratio</param_type>
            <param_value>0.86</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.06</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Geometric means</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucose AUC (Fasting)</title>
        <description>Pharmacodynamic parameter: baseline adjusted area under the glucagon concentration curve from 0 to 120 minutes</description>
        <time_frame>Approximately 15 and 0 minutes before each injection and at 5, 10, 15, 20, 30, 45, 60, and 120 minutes post-injection</time_frame>
        <population>All randomized subjects who received at least one dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>G-Pen Mini™ (Glucagon Injection) 75 ug</title>
            <description>G-Pen Mini™ (glucagon injection), a single 75 microgram subcutaneous injection given to subjects after an overnight fast</description>
          </group>
          <group group_id="O2">
            <title>G-Pen Mini™ (Glucagon Injection) 150 ug</title>
            <description>G-Pen Mini™ (glucagon injection), a single 150 microgram subcutaneous injection given given to subjects after an overnight fast</description>
          </group>
          <group group_id="O3">
            <title>G-Pen Mini™ (Glucagon Injection) 300 ug</title>
            <description>G-Pen Mini™ (glucagon injection), a single 300 microgram subcutaneous injection given given to subjects after an overnight fast</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose AUC (Fasting)</title>
          <description>Pharmacodynamic parameter: baseline adjusted area under the glucagon concentration curve from 0 to 120 minutes</description>
          <population>All randomized subjects who received at least one dose of study drug</population>
          <units>(mg/dl)*minutes</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4872.0" spread="1495.9"/>
                    <measurement group_id="O2" value="8565.2" spread="1492.8"/>
                    <measurement group_id="O3" value="12420.0" spread="1500.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3693.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1520.1</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-7548.05</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1542.93</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3854.86</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1533.95</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucose AUC (Post-insulin)</title>
        <description>Pharmacodynamic parameter: baseline adjusted area under the glucose concentration curve from 0-120 minutes</description>
        <time_frame>Approximately 15 and 0 minutes before each injection and at 5, 10, 15, 20, 30, 45, 60, and 120 minutes post-injection</time_frame>
        <population>All randomized subjects who received at least one dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>G-Pen Mini™ (Glucagon Injection) 75 ug</title>
            <description>G-Pen Mini™ (glucagon injection), a single 75 microgram subcutaneous injection given to subjects in a state of mild hypoglycemia</description>
          </group>
          <group group_id="O2">
            <title>G-Pen Mini™ (Glucagon Injection) 150 ug</title>
            <description>G-Pen Mini™ (glucagon injection), a single 150 microgram subcutaneous injection given to subjects in a state of mild hypoglycemia</description>
          </group>
          <group group_id="O3">
            <title>G-Pen Mini™ (Glucagon Injection) 300 ug</title>
            <description>G-Pen Mini™ (glucagon injection), a single 300 microgram subcutaneous injection given to subjects in a state of mild hypoglycemia</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose AUC (Post-insulin)</title>
          <description>Pharmacodynamic parameter: baseline adjusted area under the glucose concentration curve from 0-120 minutes</description>
          <population>All randomized subjects who received at least one dose of study drug</population>
          <units>(mg/dl)*minutes</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2263.2" spread="717.1"/>
                    <measurement group_id="O2" value="2408.1" spread="718.4"/>
                    <measurement group_id="O3" value="3928.5" spread="703.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-144.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>741.24</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1665.32</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>696.97</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1520.39</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>700.92</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucose Tmax (Fasting)</title>
        <description>Pharmacodynamic parameter: Time to reach maximum concentration of glucose</description>
        <time_frame>Approximately 15 and 0 minutes before each injection and at 5, 10, 15, 20, 30, 45, 60, 120 and 180 minutes post-injection</time_frame>
        <population>All randomized subjects who received at least one dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>G-Pen Mini™ (Glucagon Injection) 75 ug</title>
            <description>G-Pen Mini™ (glucagon injection), a single 75 microgram subcutaneous injection given fo subjects following an overnight fast</description>
          </group>
          <group group_id="O2">
            <title>G-Pen Mini™ (Glucagon Injection) 150 ug</title>
            <description>G-Pen Mini™ (glucagon injection), a single 150 microgram subcutaneous injection given fo subjects following an overnight fast</description>
          </group>
          <group group_id="O3">
            <title>G-Pen Mini™ (Glucagon Injection) 300 ug</title>
            <description>G-Pen Mini™ (glucagon injection), a single 300 microgram subcutaneous injection given fo subjects following an overnight fast</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose Tmax (Fasting)</title>
          <description>Pharmacodynamic parameter: Time to reach maximum concentration of glucose</description>
          <population>All randomized subjects who received at least one dose of study drug</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.5" spread="10.2"/>
                    <measurement group_id="O2" value="80.7" spread="10.2"/>
                    <measurement group_id="O3" value="67.8" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Point estimate ratio</param_type>
            <param_value>0.41</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.32</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Geometric means</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Point estimate ratio</param_type>
            <param_value>0.43</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.34</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Geometric means</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Point estimate ratio</param_type>
            <param_value>1.05</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.81</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Geometric means</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucose Tmax (Post-insulin)</title>
        <description>Pharmacodynamic parameter: Time to reach maximum concentration of glucose</description>
        <time_frame>Approximately 15 and 0 minutes before each injection and at 5, 10, 15, 20, 30, 45, 60, and 120 minutes post-injection</time_frame>
        <population>All randomized subjects who received at least one dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>G-Pen Mini™ (Glucagon Injection) 75 ug</title>
            <description>G-Pen Mini™ (glucagon injection), a single 75 microgram subcutaneous injection given to subjects in a state of mild hypoglycemia</description>
          </group>
          <group group_id="O2">
            <title>G-Pen Mini™ (Glucagon Injection) 150 ug</title>
            <description>G-Pen Mini™ (glucagon injection), a single 150 microgram subcutaneous injection given to subjects in a state of mild hypoglycemia</description>
          </group>
          <group group_id="O3">
            <title>G-Pen Mini™ (Glucagon Injection) 300 ug</title>
            <description>G-Pen Mini™ (glucagon injection), a single 300 microgram subcutaneous injection given to subjects in a state of mild hypoglycemia</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose Tmax (Post-insulin)</title>
          <description>Pharmacodynamic parameter: Time to reach maximum concentration of glucose</description>
          <population>All randomized subjects who received at least one dose of study drug</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.5" spread="7.1"/>
                    <measurement group_id="O2" value="69.5" spread="7.1"/>
                    <measurement group_id="O3" value="57.4" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Point estimate ratio</param_type>
            <param_value>0.23</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.29</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Geometric means</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Point estimate ratio</param_type>
            <param_value>0.73</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.88</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Geometric means</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Regression, Linear</method>
            <param_type>Point estimate ratio</param_type>
            <param_value>3.23</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.84</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Geometric means</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>G-Pen Mini™ (Glucagon Injection) 75 ug</title>
          <description>G-Pen Mini™ (glucagon injection), two 75 microgram subcutaneous injections given approximately 4-5 hours apart</description>
        </group>
        <group group_id="E2">
          <title>G-Pen Mini™ (Glucagon Injection) 150 ug</title>
          <description>G-Pen Mini™ (glucagon injection), two 150 microgram subcutaneous injections given approximately 4-5 hours apart</description>
        </group>
        <group group_id="E3">
          <title>G-Pen Mini™ (Glucagon Injection) 300 ug</title>
          <description>G-Pen Mini™ (glucagon injection), two 300 microgram subcutaneous injections given approximately 4-5 hours apart</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>blurred vision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>hypoglycemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Skin reaction</sub_title>
                <description>reaction to adhesive used to secure IV line</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>muscle twitching</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>paresthesia</sub_title>
                <description>in fingers</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>paresthesia</sub_title>
                <description>at injection site</description>
                <counts group_id="E1" events="13" subjects_affected="8" subjects_at_risk="12"/>
                <counts group_id="E2" events="13" subjects_affected="8" subjects_at_risk="12"/>
                <counts group_id="E3" events="16" subjects_affected="9" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>hypoesthesia</sub_title>
                <description>at injection site</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>nodule</sub_title>
                <description>at injection site</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>pain</sub_title>
                <description>at injection site</description>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>bruising</sub_title>
                <description>at injection site</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>erythema</sub_title>
                <description>at injection site</description>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="12"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>edema</sub_title>
                <description>at injection site</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Martin J. Cummins, VP Drug Development</name_or_title>
      <organization>Xeris Pharmaceuticals, Inc.</organization>
      <phone>512-498-2675</phone>
      <email>mjcummins@xerispharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

